cytosine has been researched along with Kahler Disease in 14 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| " Future studies will be needed to address modified dosing according to emerging pharmacokinetic and pharmacodynamic data and combination therapy which may lead to improved clinical benefit for troxacitabine in hematologic malignancies." | 6.73 | A phase II multicenter study of troxacitabine in relapsed or refractory lymphoproliferative neoplasms or multiple myeloma. ( Baccarani, M; Belanger, R; Ben-Yehuda, D; Caballero, D; Coiffier, B; Facon, T; Fanin, R; Giles, F; Gregory, SA; Panwalkar, A; Vose, JM, 2007) |
| "In an analysis of >800 primary multiple myelomas, MAX alterations occurred at a frequency of ∼3%, more than half of which were single nucleotide substitutions affecting a basic clamp-like interface important for DNA interaction." | 5.46 | MAX is an epigenetic sensor of 5-carboxylcytosine and is altered in multiple myeloma. ( Barwick, BG; Boise, LH; Cheng, X; Hashimoto, H; Lonial, S; Vertino, PM; Wang, D; Zhang, X, 2017) |
| " Nucleoside analogs in development for non-Hodgkin's lymphoma (NHL) include clofarabine, troxacitabine, and bendamustine, a hybrid of an alkylating nitrogen mustard group and a purine-like benzimidazole, with demonstrated activity in NHL." | 4.81 | Hematologic malignancies: new developments and future treatments. ( Cheson, BD, 2002) |
| " Future studies will be needed to address modified dosing according to emerging pharmacokinetic and pharmacodynamic data and combination therapy which may lead to improved clinical benefit for troxacitabine in hematologic malignancies." | 2.73 | A phase II multicenter study of troxacitabine in relapsed or refractory lymphoproliferative neoplasms or multiple myeloma. ( Baccarani, M; Belanger, R; Ben-Yehuda, D; Caballero, D; Coiffier, B; Facon, T; Fanin, R; Giles, F; Gregory, SA; Panwalkar, A; Vose, JM, 2007) |
| "In an analysis of >800 primary multiple myelomas, MAX alterations occurred at a frequency of ∼3%, more than half of which were single nucleotide substitutions affecting a basic clamp-like interface important for DNA interaction." | 1.46 | MAX is an epigenetic sensor of 5-carboxylcytosine and is altered in multiple myeloma. ( Barwick, BG; Boise, LH; Cheng, X; Hashimoto, H; Lonial, S; Vertino, PM; Wang, D; Zhang, X, 2017) |
| "The cause of follicular spicules in multiple myeloma (MM) is not known." | 1.42 | Cidofovir gel as treatment of follicular spicules in multiple myeloma. ( Feltkamp, MC; Fouchier, RA; Hajdarbegovic, E; Jones, T; Muhlemann, B; van Boheemen, S, 2015) |
| "A patient with multiple myeloma was treated with high-dose chemotherapy followed by two autologous bone marrow transplantations (ABMTs)." | 1.37 | Progressive multifocal leucoencephalopathy after autologous bone marrow transplantation: a treatment option. ( Brustia, D; Cantello, R; Comi, C; Conconi, A; De Paoli, L; Gaidano, G; Monaco, F; Mula, M; Nasuelli, N; Ripellino, P; Savio, K; Stecco, A; Varrasi, C, 2011) |
| "For instance, multiple myeloma is characterized by frequent karyotypic instability at the earliest stage, progressing to extreme genetic abnormalities as the disease progresses." | 1.33 | Epigenetic silencing of the human nucleotide excision repair gene, hHR23B, in interleukin-6-responsive multiple myeloma KAS-6/1 cells. ( Cherry, JM; Farrar, WL; Hodge, DR; Munroe, DJ; Peng, B; Pompeia, C; Thomas, SB; Xiao, W, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (14.29) | 18.7374 |
| 1990's | 1 (7.14) | 18.2507 |
| 2000's | 4 (28.57) | 29.6817 |
| 2010's | 7 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| van Boheemen, S | 2 |
| Jones, T | 1 |
| Muhlemann, B | 1 |
| Feltkamp, MC | 1 |
| Fouchier, RA | 2 |
| Hajdarbegovic, E | 2 |
| Hosler, GA | 1 |
| Weibel, L | 1 |
| Wang, RC | 1 |
| Reardon, S | 1 |
| Sztanke, M | 1 |
| Rzymowska, J | 1 |
| Sztanke, K | 1 |
| Wang, D | 1 |
| Hashimoto, H | 1 |
| Zhang, X | 1 |
| Barwick, BG | 1 |
| Lonial, S | 1 |
| Boise, LH | 1 |
| Vertino, PM | 1 |
| Cheng, X | 1 |
| Ripellino, P | 1 |
| Comi, C | 1 |
| Mula, M | 1 |
| Varrasi, C | 1 |
| Conconi, A | 1 |
| Stecco, A | 1 |
| Brustia, D | 1 |
| Nasuelli, N | 1 |
| Savio, K | 1 |
| De Paoli, L | 1 |
| Cantello, R | 1 |
| Gaidano, G | 1 |
| Monaco, F | 1 |
| Cheson, BD | 1 |
| Peng, B | 1 |
| Hodge, DR | 1 |
| Thomas, SB | 1 |
| Cherry, JM | 1 |
| Munroe, DJ | 1 |
| Pompeia, C | 1 |
| Xiao, W | 1 |
| Farrar, WL | 1 |
| Vose, JM | 1 |
| Panwalkar, A | 1 |
| Belanger, R | 1 |
| Coiffier, B | 1 |
| Baccarani, M | 1 |
| Gregory, SA | 1 |
| Facon, T | 1 |
| Fanin, R | 1 |
| Caballero, D | 1 |
| Ben-Yehuda, D | 1 |
| Giles, F | 1 |
| Nicolasora, NP | 1 |
| Reddy, P | 1 |
| Kaul, DR | 1 |
| Watts, GS | 1 |
| Futscher, BW | 1 |
| Chen, EY | 2 |
| Roe, BA | 2 |
| Tsen, HY | 1 |
1 review available for cytosine and Kahler Disease
| Article | Year |
|---|---|
Hematologic malignancies: new developments and future treatments.
Topics: Adenine Nucleotides; Alemtuzumab; Alkaloids; Antibodies, Monoclonal; Antibodies, Monoclonal, Humaniz | 2002 |
1 trial available for cytosine and Kahler Disease
| Article | Year |
|---|---|
A phase II multicenter study of troxacitabine in relapsed or refractory lymphoproliferative neoplasms or multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents; Cytosine; Dioxolanes; Dose-Response Relationship, Drug; Drug Res | 2007 |
12 other studies available for cytosine and Kahler Disease
| Article | Year |
|---|---|
Cidofovir gel as treatment of follicular spicules in multiple myeloma.
Topics: Aged; Antiviral Agents; Carcinoma, Merkel Cell; Cidofovir; Cytosine; Gels; Hair Follicle; Humans; Ma | 2015 |
The cause of follicular spicules in multiple myeloma.
Topics: Carcinoma, Merkel Cell; Cytosine; Humans; Male; Multiple Myeloma; Organophosphonates; Skin Neoplasms | 2015 |
The cause of follicular spicules in multiple myeloma-reply.
Topics: Carcinoma, Merkel Cell; Cytosine; Humans; Male; Multiple Myeloma; Organophosphonates; Skin Neoplasms | 2015 |
Fairer way to distribute last-ditch drugs gets real-world trial.
Topics: Antibodies, Monoclonal; Child; Compassionate Use Trials; Controlled Clinical Trials as Topic; Cytosi | 2016 |
In vitro effects of a new fused azaisocytosine-like congener on relative cell proliferation, necrosis and cell cycle in cancer and normal cell cultures.
Topics: Cell Division; Cytosine; G2 Phase; HeLa Cells; Humans; Multiple Myeloma | 2016 |
MAX is an epigenetic sensor of 5-carboxylcytosine and is altered in multiple myeloma.
Topics: Arginine; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; CpG Islands; Cytosine; DNA; E | 2017 |
Progressive multifocal leucoencephalopathy after autologous bone marrow transplantation: a treatment option.
Topics: Antidepressive Agents, Tricyclic; Antiviral Agents; Bone Marrow Transplantation; Cidofovir; Cytosine | 2011 |
Epigenetic silencing of the human nucleotide excision repair gene, hHR23B, in interleukin-6-responsive multiple myeloma KAS-6/1 cells.
Topics: Base Sequence; Cell Line, Tumor; CpG Islands; Culture Media; Cytidine; Cytosine; DNA; DNA Damage; DN | 2005 |
Biopsy-proven adenoviral diarrhea responding to low-dose cidofovir.
Topics: Adenoviridae; Adenovirus Infections, Human; Aged; Antigens, Viral; Antiviral Agents; Biopsy; Cidofov | 2008 |
Detecting differences in 5-methylcytosine using restriction enzyme isoschizomers: an endogenous control for complete digestion.
Topics: 5-Methylcytosine; Animals; Base Sequence; Blotting, Southern; Cell Line; Cytosine; DNA Restriction E | 1995 |
Sequence studies on human placenta tRNAVal : comparison with the mouse myeloma tRNAVal.
Topics: Animals; Anticodon; Base Sequence; Cytosine; Female; Humans; Mice; Multiple Myeloma; Placenta; Pregn | 1977 |
Studies on the ribothymidine content of specific rat and human tRNAs: a postulated role for 5-methyl cytosine in the regulation of ribothymidine biosynthesis.
Topics: Animals; Base Sequence; Binding Sites; Cytosine; Female; Humans; Liver; Mice; Multiple Myeloma; Nucl | 1976 |